CANCER TREATMENT REGIMENS
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies.
These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Sign Up for Free e-newsletters
Cancer Therapy Advisor Articles
- Pembrolizumab vs. Chemo for Ipilimumab-Refractory Melanoma
- Filgrastim Biosimilar Appears Equally Safe, Effective for Breast Cancer
- Anabolic Response of Essential Amino Acid Mixtures in Advanced Lung Cancer
- Bevacizumab with Chemo Improves Survival in Ovarian Cancer with Poor Prognosis
- Prostate Cancer Androgen Deprivation and Chemo: Does Timing Matter?
- Older Adults with Head and Neck Cancers May Need More Cautious Treatment Strategies
- Nivolumab Shows Promising Efficacy, Safety in Advanced Hepatocellular Carcinoma
- Results of Nivolumab CheckMate 057 Study May Change Treatment of Lung Cancer
- Bortezomib Consolidation More Effective Than Observation for Newly Diagnosed Multiple Myeloma
- Link Between Citrus Consumption and Melanoma
- Statin Therapy May Help Delay Prostate Cancer Progression in Men Receiving ADT
- Ibrutinib Plus Ofatumumab Tolerable, Active for Relapsed CLL
- Prior Myeloproliferative Neoplasm Associated with Poor Outlook in Patients with New Primary Cancers
- Prognostic Significance of Minimal Residual Disease in Pediatric B-ALL
- T-VEC Immunotherapy Demonstrates Activity Against Locally Advanced Melanoma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|